Therakos
1 known investors
Therakos develops THERAKOS Photopheresis, an FDA-approved extracorporeal photopheresis (ECP) system used to treat skin symptoms of cutaneous T-cell lymphoma (CTCL) unresponsive to other treatments. It provides medical devices and associated drug therapy for clinicians treating CTCL patients.
Investors · 1
Frequently asked questions
- What does Therakos do?
- Therakos develops THERAKOS Photopheresis, an FDA-approved extracorporeal photopheresis (ECP) system used to treat skin symptoms of cutaneous T-cell lymphoma (CTCL) unresponsive to other treatments. It provides medical devices and associated drug therapy for clinicians treating CTCL patients.
- Who are Therakos's investors?
- Therakos's investors include Gores.